SUBSCRIBE
SUBSCRIBE
News   Policy

FDA to Review Arcoxia, Merck & Co., Inc.'s (Jobs) Follow-Up to Vioxx

March 5, 2007 | 
1 min read
A Food and Drug Administration panel in April will review Merck's Arcoxia, its follow-up to the controversial painkiller Vioxx, which was pulled from the market in 2004 following safety concerns.

>>> Discuss This Story

Regulatory
Merck & Co. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Vaccine and syringe injection. Doctor hand with syringe. Vaccination of people for prevention, immunization and treatment from virus infection. Medicine, flu shot, test with needle. Vector
Adcomms
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm
May 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Richard Pazdur
Regulatory
Pazdur declines to announce candidacy for vacated FDA commissioner role
May 20, 2026
 · 
4 min read
 · 
Heather McKenzie
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 2026
 · 
1 min read
 · 
Jef Akst
The COVID-19 vaccine in glass bottles for prevention, immunization, and treatment of coronavirus infection on a green background. Space for text. Concept of medical and vaccine.
COVID-19
FDA’s own report shows no child deaths definitively caused by COVID vaccination
May 19, 2026
 · 
3 min read
 · 
Tristan Manalac